BCOP Updates 2025: Updates in Upper GI Cancers
The treatment paradigm for upper gastrointestinal cancers has been rapidly shifting. In the past 5 years, there has been an influx of data regarding immunotherapy and new treatment options for gastric and esophageal cancers, including a dozen new or revised FDA-approvals. This session will review updates in the treatment of gastric and esophageal cancers and will help to define optimal therapy selection for patients with these upper gastrointestinal cancers.
BCOP Updates 2025: Updates in Upper GI Cancers
Author: Sarah K. Cimino, PharmD, BCOP
Learning Objectives
- Select the best treatment regimen for a patient with esophageal squamous cell carcinoma
- Based on patient-specific characteristics, determine the best first-line treatment regimen for a patient with HER2+ gastric adenocarcinoma
- Describe claudin 18.2 and the mechanism of action of zolbetuximab
- Summarize ongoing clinical trials for the treatment of gastric and esophageal cancers
Get it now!
Knowledge Course for Pharmacists
Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.
All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.